Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

25 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Personality assessment with Temperament and Character Inventory in Parkinson's disease.
Boussac M, Arbus C, Colin O, Laurencin C, Eusebio A, Hainque E, Corvol JC, Versace N, Rascol O, Rousseau V, Harroch E, Ory-Magne F, Fabbri M, Moreau C, Rolland AS, Jarraya B, Maltête D, Drapier S, Marques AR, Auzou N, Wirth T, Meyer M, Giordana B, Tir M, Rouaud T, Devos D, Brefel-Courbon C; PREDISTIM study group. Boussac M, et al. Among authors: colin o. Parkinsonism Relat Disord. 2022 Oct;103:34-41. doi: 10.1016/j.parkreldis.2022.08.004. Epub 2022 Aug 19. Parkinsonism Relat Disord. 2022. PMID: 36030666 Free article.
Understand, elucidate and rationalize the coordination mode of pyrimidylmethylamines: an intertwined study combining NMR and DFT methods.
Herbert Pucheta JE, Candy M, Colin O, Requet A, Bourdreux F, Galmiche-Loire E, Gaucher A, Thomassigny C, Prim D, Mahfoudh M, Leclerc E, Campagne JM, Farjon J. Herbert Pucheta JE, et al. Among authors: colin o. Phys Chem Chem Phys. 2015 Apr 14;17(14):8740-9. doi: 10.1039/c5cp00241a. Epub 2015 Mar 4. Phys Chem Chem Phys. 2015. PMID: 25739103
Quality of life predicts outcome of deep brain stimulation in early Parkinson disease.
Schuepbach WMM, Tonder L, Schnitzler A, Krack P, Rau J, Hartmann A, Hälbig TD, Pineau F, Falk A, Paschen L, Paschen S, Volkmann J, Dafsari HS, Barbe MT, Fink GR, Kühn A, Kupsch A, Schneider GH, Seigneuret E, Fraix V, Kistner A, Chaynes PP, Ory-Magne F, Brefel-Courbon C, Vesper J, Wojtecki L, Derrey S, Maltête D, Damier P, Derkinderen P, Sixel-Döring F, Trenkwalder C, Gharabaghi A, Wächter T, Weiss D, Pinsker MO, Regis JM, Witjas T, Thobois S, Mertens P, Knudsen K, Schade-Brittinger C, Houeto JL, Agid Y, Vidailhet M, Timmermann L, Deuschl G; EARLYSTIM study group. Schuepbach WMM, et al. Neurology. 2019 Mar 5;92(10):e1109-e1120. doi: 10.1212/WNL.0000000000007037. Epub 2019 Feb 8. Neurology. 2019. PMID: 30737338 Free PMC article. Clinical Trial.
Intrasubject subcortical quantitative referencing to boost MRI sensitivity to Parkinson's disease.
Khedher L, Bonny JM, Marques A, Durand E, Pereira B, Chupin M, Vidal T, Chassain C, Defebvre L, Carriere N, Fraix V, Moro E, Thobois S, Metereau E, Mangone G, Vidailhet M, Corvol JC, Lehéricy S, Menjot de Champfleur N, Geny C, Spampinato U, Meissner W, Frismand S, Schmitt E, Doé de Maindreville A, Portefaix C, Remy P, Fénelon G, Luc Houeto J, Colin O, Rascol O, Peran P, Durif F; R study group. Khedher L, et al. Among authors: colin o. Neuroimage Clin. 2022;36:103231. doi: 10.1016/j.nicl.2022.103231. Epub 2022 Oct 12. Neuroimage Clin. 2022. PMID: 36279753 Free PMC article.
Volumetric changes and clinical trajectories in Parkinson's disease: a prospective multicentric study.
Marques A, Macias E, Pereira B, Durand E, Chassain C, Vidal T, Defebvre L, Carriere N, Fraix V, Moro E, Thobois S, Metereau E, Mangone G, Vidailhet M, Corvol JC, Lehéricy S, Menjot de Champfleur N, Geny C, Spampinato U, Meissner WG, Frismand S, Schmitt E, Doé de Maindreville A, Portefaix C, Remy P, Fénelon G, Houeto JL, Colin O, Rascol O, Peran P, Bonny JM, Fantini ML, Durif F; R2* Study Group. Marques A, et al. Among authors: colin o. J Neurol. 2023 Dec;270(12):6033-6043. doi: 10.1007/s00415-023-11947-0. Epub 2023 Aug 31. J Neurol. 2023. PMID: 37648911
Trial of Botulinum Toxin for Isolated or Essential Head Tremor.
Marques A, Pereira B, Simonetta-Moreau M, Castelnovo G, De Verdal M, Fluchère F, Laurencin C, Degos B, Tir M, Kreisler A, Blanchet-Fourcade G, Guehl D, Colin O, Poujois A, Sangla S, Tatu L, Derost P, Gayraud D, Tranchant C, Amarantini D, Devos D, Rascol O, Corvol JC, Durif F, Rieu I; Btx-HT Study Group. Marques A, et al. Among authors: colin o. N Engl J Med. 2023 Nov 9;389(19):1753-1765. doi: 10.1056/NEJMoa2304192. N Engl J Med. 2023. PMID: 37937777 Clinical Trial.
A Double-Blind, Randomized, Placebo-Controlled Trial of Bumetanide in Parkinson's Disease.
Damier P, Degos B, Castelonovo G, Anheim M, Benatru I, Carrière N, Colin O, Defebvre L, Deverdal M, Eusebio A, Ferrier V, Giordana C, Houeto JL, Le Dily S, Mongin M, Thiriez C, Tranchant C, Ravel D, Corvol JC, Rascol O, Ben Ari Y. Damier P, et al. Among authors: colin o. Mov Disord. 2024 Mar;39(3):618-622. doi: 10.1002/mds.29726. Epub 2024 Jan 30. Mov Disord. 2024. PMID: 38291616 Clinical Trial.
Trial of Lixisenatide in Early Parkinson's Disease.
Meissner WG, Remy P, Giordana C, Maltête D, Derkinderen P, Houéto JL, Anheim M, Benatru I, Boraud T, Brefel-Courbon C, Carrière N, Catala H, Colin O, Corvol JC, Damier P, Dellapina E, Devos D, Drapier S, Fabbri M, Ferrier V, Foubert-Samier A, Frismand-Kryloff S, Georget A, Germain C, Grimaldi S, Hardy C, Hopes L, Krystkowiak P, Laurens B, Lefaucheur R, Mariani LL, Marques A, Marse C, Ory-Magne F, Rigalleau V, Salhi H, Saubion A, Stott SRW, Thalamas C, Thiriez C, Tir M, Wyse RK, Benard A, Rascol O; LIXIPARK Study Group. Meissner WG, et al. Among authors: colin o. N Engl J Med. 2024 Apr 4;390(13):1176-1185. doi: 10.1056/NEJMoa2312323. N Engl J Med. 2024. PMID: 38598572 Clinical Trial.
25 results